The evaluation of PIK3CA gene variation and serum PI3K level in breast cancer risk and prognosis in Turkish population

被引:2
作者
Ulu, Elif [1 ]
Yaylim, Ilhan [1 ]
Arikan, Soykan [2 ]
Cacina, Canan [1 ]
机构
[1] Istanbul Univ, Dept Mol Med, Aziz Sancar Inst Expt Med, Istanbul, Turkey
[2] Istanbul Educ & Res Hosp, Gen Surg Clin, Istanbul, Turkey
来源
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI | 2022年 / 47卷 / 03期
关键词
apoptosis; breast cancer; phosphatidylinositol-4; 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA); serum level; single nucleotide polymorphism (SNP); apoptoz; Meme kanseri; Fosfatidilinozitol-4; 5-bifosfat 3-kinaz katalitik alt birim alfa (PIK3CA); serum duzeyi; tek nukleotid polimorfizmi (SNP); PHOSPHOINOSITIDE 3-KINASE PATHWAY; SINGLE NUCLEOTIDE POLYMORPHISMS; PI3K/AKT/MTOR PATHWAY; CLINICAL-OUTCOMES; CELL CARCINOMA; ASSOCIATION; MUTATION; VARIANTS; DNA;
D O I
10.1515/tjb-2021-0072
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Objectives The PI3K (Phosphatidylinositol 3-kinase) is the member of lipid kinase family that plays important roles in tumorigenesis, cancer development and cell proliferation. In our study, we aimed to investigate the relationships between breast cancer risk and prognosis with PIK3CA rs6443624 (C>A) intron region gene polymorphism and serum PI3K levels. Methods A total of 61-patients with breast cancer and 101 controls were included to the study. PIK3CA polymorphism was detected by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) technique. Serum PI3K levels were measured by Enzyme-Linked Immuno Sorbent Assay (ELISA). Results PIK3CA (C>A) gene polymorphism genotype and allele distributions were no significant in cases and controls (p>0.05). The serum PI3K levels of breast cancer patients were found significantly higher than the control groups (p=0.033). There were not significant association between PIK3CA (C>A) gene polymorphism and clinic and prognostic parameters in our study group. We also evaluated serum PI3K levels in the term of tumor progression, but we did not observe any significant data. Conclusions We suggest that serum PI3K levels may play role in breast cancer risk and larger patient groups may have clinical value in assessment of the genetic risk and tumor progression of breast cancer.
引用
收藏
页码:317 / 324
页数:8
相关论文
共 38 条
  • [1] PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
    Abraham, Jame
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 51 - 68
  • [2] Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients
    Ahmad, Firoz
    Badwe, Anuya
    Verma, Geeta
    Bhatia, Simi
    Das, Bibhu Ranjan
    [J]. MEDICAL ONCOLOGY, 2016, 33 (07)
  • [3] PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis
    Alqahtani, Ali
    Ayesh, Hazem S. K.
    Halawani, Hafez
    [J]. CANCERS, 2020, 12 (01)
  • [4] The phosphoinositide 3-kinase pathway in human cancer: Genetic alterations and therapeutic implications
    Arcaro, Alexandre
    Guerreiro, Ana S.
    [J]. CURRENT GENOMICS, 2007, 8 (05) : 271 - 306
  • [5] ASSOCIATION BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS IN THE PI3K/AKT/MTOR PATHWAY AND BLADDER CANCER RISK IN A SAMPLE OF IRANIAN POPULATION
    Bizhani, Fatemeh
    Hashemi, Mohammad
    Danesh, Hiva
    Nouralizadeh, Akbar
    Narouie, Behzad
    Bahari, Gholamreza
    Ghavami, Saeid
    [J]. EXCLI JOURNAL, 2018, 17 : 3 - 13
  • [6] Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines
    Bodnar, L.
    Stec, R.
    Cierniak, S.
    Synowiec, A.
    Wcislo, G.
    Jesiotr, M.
    Koktysz, R.
    Kozlowski, W.
    Szczylik, C.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (07) : 1385 - 1389
  • [7] PTEN and the PI3-Kinase Pathway in Cancer
    Chalhoub, Nader
    Baker, Suzanne J.
    [J]. ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2009, 4 : 127 - 150
  • [8] Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer
    Dirican, Ebubekir
    Akkiprik, Mustafa
    Ozer, Ayse
    [J]. TUMOR BIOLOGY, 2016, 37 (06) : 7033 - 7045
  • [9] Targeting PI3K signalling in cancer: opportunities, challenges and limitations
    Engelman, Jeffrey A.
    [J]. NATURE REVIEWS CANCER, 2009, 9 (08) : 550 - 562
  • [10] Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
    Feng, Yixiao
    Spezia, Mia
    Huang, Shifeng
    Yuan, Chengfu
    Zeng, Zongyue
    Zhang, Linghuan
    Ji, Xiaojuan
    Liu, Wei
    Huang, Bo
    Luo, Wenping
    Liu, Bo
    Lei, Yan
    Du, Scott
    Vuppalapati, Akhila
    Luu, Hue H.
    Haydon, Rex C.
    He, Tong-Chuan
    Ren, Guosheng
    [J]. GENES & DISEASES, 2018, 5 (02) : 77 - 106